Aliases & Classifications for Withdrawal Disorder

MalaCards integrated aliases for Withdrawal Disorder:

Name: Withdrawal Disorder 12 15
Withdrawal Syndrome 54 15
Substance Withdrawal Syndrome 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0060001
UMLS 71 C0038587

Summaries for Withdrawal Disorder

Disease Ontology : 12 A substance-related disorder that occurs upon the abrupt discontinuation/separation or a decrease in dosage of the intake of medications, recreational drugs, and alcohol.

MalaCards based summary : Withdrawal Disorder, also known as withdrawal syndrome, is related to heroin dependence and neonatal abstinence syndrome, and has symptoms including seizures, opiate withdrawal symptoms and drug withdrawal symptoms. An important gene associated with Withdrawal Disorder is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Acetylcholine and Diazepam have been mentioned in the context of this disorder. Affiliated tissues include brain, prostate and heart, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Withdrawal Disorder

Diseases related to Withdrawal Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 271)
# Related Disease Score Top Affiliating Genes
1 heroin dependence 32.0 PDYN OPRM1 OPRD1 DRD2 DRD1
2 neonatal abstinence syndrome 31.5 PNOC PDYN OPRM1 OPRL1 OPRK1 OPRD1
3 diarrhea 30.4 POMC OPRM1 OPRK1 OPRD1
4 status epilepticus 30.3 TSPO FOS DRD2
5 alcohol use disorder 30.3 OPRM1 DRD2 DRD1 CRHR1 CRH
6 opioid addiction 30.2 PNOC OPRM1 OPRK1 OPRD1 DRD2
7 opiate dependence 30.2 POMC PENK PDYN OPRM1 OPRL1 OPRK1
8 barbiturate abuse 30.1 OPRM1 MLST8
9 personality disorder 30.1 DRD2 CRHR1 CRH
10 motion sickness 29.9 POMC OPRM1 FOS CNR1
11 cannabis dependence 29.9 PENK FAAH DRD2 CNR1
12 bulimia nervosa 29.8 POMC DRD2 CRH CNR1
13 polysubstance abuse 29.7 FAAH DRD2 CNR1
14 impulse control disorder 29.7 OPRM1 DRD2 DRD1
15 borderline personality disorder 29.7 DRD2 CRHR1 CRH
16 generalized anxiety disorder 29.6 TSPO DRD2 CRHR1
17 morphine dependence 29.6 PENK PDYN OPRM1 OPRL1 OPRK1 OPRD1
18 psychotic disorder 29.5 PDYN OPRM1 DRD2 DRD1 CNR1
19 mood disorder 29.5 POMC DRD2 DRD1 CRHR1 CRH
20 tobacco addiction 29.3 PDYN OPRM1 DRD2 DRD1 CRHR1 CRH
21 eating disorder 29.3 POMC OPRM1 FAAH DRD2 CRH CNR1
22 attention deficit-hyperactivity disorder 29.3 TSPO OPRM1 FOS DRD2 DRD1
23 panic disorder 29.1 TSPO POMC DRD2 DRD1 CRHR1 CRH
24 constipation 29.0 PDYN OPRM1 OPRL1 OPRK1 OPRD1 FAAH
25 cocaine dependence 28.6 POMC PDYN OPRM1 OPRK1 OPRD1 DRD2
26 body mass index quantitative trait locus 11 28.3 POMC FOS FAAH DRD2 CRHR1 CRH
27 alcohol dependence 28.3 TSPO POMC PNOC PDYN OPRM1 OPRL1
28 anxiety 28.3 TSPO POMC PNOC PDYN OPRM1 OPRL1
29 pain agnosia 28.3 POMC PNOC PENK PDYN OPRM1 OPRL1
30 substance dependence 28.1 POMC PDYN OPRM1 OPRL1 OPRK1 OPRD1
31 substance abuse 28.1 POMC PDYN OPRM1 OPRL1 OPRK1 OPRD1
32 drug dependence 27.8 POMC PNOC PENK PDYN OPRM1 OPRL1
33 migraine with or without aura 1 27.2 POMC PNOC PDYN OPRM1 OPRL1 OPRK1
34 barbiturate dependence 11.4
35 subacute delirium 10.6
36 prostate leiomyoma 10.6 KLK3 AR
37 tremor 10.5
38 prostate calculus 10.5 KLK3 AR
39 cyclic vomiting syndrome 10.5 OPRM1 CNR1
40 prostatic acinar adenocarcinoma 10.5 KLK3 AR
41 uremic pruritus 10.5 OPRK1 CNR1
42 acth-dependent cushing syndrome 10.4 POMC CRH
43 prostate adenoid cystic carcinoma 10.4 POMC KLK3 AR
44 tuberculous epididymitis 10.4 POMC KLK3
45 pituitary infarct 10.4 POMC CRH
46 autoimmune encephalitis 10.4 FAAH CNR1
47 kleptomania 10.4 OPRK1 DRD2
48 prostate neuroendocrine neoplasm 10.4 KLK3 AR
49 prolactin producing pituitary tumor 10.4 POMC DRD2
50 fasting hypoglycemia 10.3 POMC CRH

Graphical network of the top 20 diseases related to Withdrawal Disorder:



Diseases related to Withdrawal Disorder

Symptoms & Phenotypes for Withdrawal Disorder

UMLS symptoms related to Withdrawal Disorder:


seizures, opiate withdrawal symptoms, drug withdrawal symptoms, withdrawal symptoms

GenomeRNAi Phenotypes related to Withdrawal Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 9.47 FOS
2 Decreased viability GR00221-A-1 9.47 MLST8
3 Decreased viability GR00221-A-4 9.47 MLST8
4 Decreased viability GR00249-S 9.47 CRHR1 FOS NCOA4 OPRK1 OPRL1
5 Decreased viability GR00386-A-1 9.47 DRD1 NCOA4 OPRL1 POMC
6 Decreased viability GR00402-S-2 9.47 OPRK1 OPRM1

MGI Mouse Phenotypes related to Withdrawal Disorder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 AR CNR1 CRH CRHR1 DRD1 DRD2
2 homeostasis/metabolism MP:0005376 10.25 AR CNR1 CRH CRHR1 DRD1 DRD2
3 growth/size/body region MP:0005378 10.15 AR CNR1 CRH DRD1 DRD2 FOS
4 adipose tissue MP:0005375 10.13 AR CNR1 CRH DRD1 DRD2 FOS
5 integument MP:0010771 10.13 AR CNR1 CRH DRD1 DRD2 FAAH
6 endocrine/exocrine gland MP:0005379 10.1 AR CRH CRHR1 DRD2 FOS OPRK1
7 nervous system MP:0003631 10.03 AR CNR1 CRH CRHR1 DRD1 DRD2
8 digestive/alimentary MP:0005381 9.98 AR CNR1 DRD1 DRD2 OPRK1 OPRM1
9 no phenotypic analysis MP:0003012 9.61 CNR1 CRH CRHR1 DRD2 OPRD1 OPRM1
10 normal MP:0002873 9.4 AR CNR1 CRH CRHR1 DRD1 DRD2

Drugs & Therapeutics for Withdrawal Disorder

Drugs for Withdrawal Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 212)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
2
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
3
Lofexidine Approved, Investigational Phase 4 31036-80-3 30668
4
Sodium oxybate Approved Phase 4 502-85-2 5360545
5
Oxazepam Approved Phase 4 604-75-1 4616
6
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
7
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
8
Loperamide Approved Phase 4 53179-11-6 3955
9
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
10
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
11
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
12
Xylometazoline Approved, Investigational Phase 4 526-36-3 5709
13
Flumazenil Approved Phase 4 78755-81-4 3373
14
Haloperidol Approved Phase 4 52-86-8 3559
15
Nicotine Approved Phase 4 54-11-5 942 89594
16
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
17
Chlordiazepoxide Approved, Illicit, Investigational Phase 4 58-25-3 2712
18
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
19
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
20
Clonidine Approved Phase 4 4205-90-7 2803
21
Morphine Approved, Investigational Phase 4 57-27-2 5288826
22
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
23
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
24
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
25
tannic acid Approved Phase 4 1401-55-4
26
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
27
Esmolol Approved Phase 4 103598-03-4, 81147-92-4 59768
28
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
29
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
30 Opiate Alkaloids Phase 4
31 Adjuvants, Immunologic Phase 4
32 Central Nervous System Stimulants Phase 4
33 Protective Agents Phase 4
34 Dopamine Agents Phase 4
35 Dopamine Antagonists Phase 4
36 phenazepam Phase 4 40113
37 Antidiarrheals Phase 4
38 Cyclooxygenase Inhibitors Phase 4
39 Anti-Inflammatory Agents Phase 4
40 Anti-Inflammatory Agents, Non-Steroidal Phase 4
41 Pharmaceutical Solutions Phase 4
42 Antidotes Phase 4
43 Detox adjuvant Phase 4
44 Sodium Channel Blockers Phase 4
45 Diuretics, Potassium Sparing Phase 4
46 Antineoplastic Agents, Hormonal Phase 4
47 glucocorticoids Phase 4
48 Haloperidol decanoate Phase 4
49 Nicotinic Agonists Phase 4
50 Cholinergic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 175)
# Name Status NCT ID Phase Drugs
1 Prospective Assessment of Valproate on Ethanol Withdrawal Unknown status NCT03235531 Phase 4 Valproate;Lorazepam
2 A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine Completed NCT03698331 Phase 4 Valbenazine;Placebo oral capsule
3 The Gamma Hydroxybutyric Acid in Alcohol-dependence Treatment Efficacy (GATE) I Trial: a Comparative Study Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome Completed NCT02090504 Phase 4 Sodium Oxybate (SMO);Oxazepam
4 Nicotine Replacement Therapy in the Intensive Care Unit: a Randomized, Controlled Pilot Study Completed NCT01362959 Phase 4 Transdermal nicotine patch
5 A Behavioral Assessment of Electronic Cigarettes in Reducing Cue- and Withdrawal-induced Craving in Daily Dependent Smokers Completed NCT02108626 Phase 4 Nicotine;Placebo
6 Randomized Clinical Trial of Pregabalin for Opioid Withdrawal Syndrome Completed NCT03017430 Phase 4 Pregabalin;Clonidine;Doxylamin;Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)
7 Acute Drug Withdrawal in a General Medical Setting Completed NCT00249366 Phase 4 Lorazepam (drug);Lorazepam
8 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4 Buprenorphine;Valproate
9 Treatment Of Alcohol Withdrawal Syndrome: Dexmedetomidine Vs Diazepam In A Hospital O'horán Completed NCT03877120 Phase 4 Dexmedetomidine 0.004 MG/ML;Diazepam Injectable Solution
10 Carbamazepine and Lorazepam in Outpatient Detoxification Completed NCT00000441 Phase 4 lorazepam (Ativan);carbamazepine (Tegretol)
11 Comparison of Chlordiazepoxide and Gabapentin for Outpatient Alcohol Detoxification Treatment Completed NCT01573052 Phase 4 Chlordiazepoxide;Gabapentin
12 Efficiency and Safety Study of Short-term Prednisone to Treat Moderate and Severe Subacute Thyroiditis Completed NCT01837433 Phase 4 Prednisone 1 week;Prednisone 6 weeks
13 Effect of Flumazenil on Hypoactive Delirium Secondary to Benzodiazepine Toxicity in the ICU Completed NCT02899156 Phase 4 Flumazenil;Placebo
14 Dexmedetomidine Addition to Benzodiazepines for Patients With Alcohol Withdrawal Syndrome in the ICU: a Randomised Controlled Study Completed NCT02496650 Phase 4 Dexmedetomidine
15 A Double-blind Randomised Controlled Clinical Trial of Lofexidine Versus Diazepam in the Management of the Opioid Withdrawal Syndrome During Inpatient Detoxification in Singapore Completed NCT01675648 Phase 4 Lofexidine;Diazepam;Placebo for Lofexidine;Placebo for Diazepam
16 A Double-Blind, Placebo-Controlled Trial of Reward Responsivity During Nicotine Withdrawal in Smokers With Schizophrenia and Normal Controls Completed NCT00373126 Phase 4 transdermal nicotine patch
17 A Prospective Randomized Controlled Open Label Trial of Symptom-triggered Benzodiazepine Versus Fixed-dose Gabapentin for Alcohol Withdrawal Syndrome Recruiting NCT03012815 Phase 4 Gabapentin;Benzodiazepines;Divalproex Sodium
18 Varenicline OTC Trial on Efficacy and Safety Recruiting NCT03557294 Phase 4 1.0mg Varenicline b.i.d.;0.5mg Varenicline b.i.d.;0.0mg placebo Varenicline b.i.d.
19 Efficacy and Safety of the Administration of the Passiflora Extract for Benzodiazepine Withdrawal in Institutionalized Older Adults: Clinical Trial Phase III Recruiting NCT03780595 Phase 4 Passiflora incarnata;Control
20 Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy Recruiting NCT03092011 Phase 4 Clonidine;Morphine Sulfate
21 Using Imaging to Assess Effects of THC on Brain Activity Recruiting NCT03655717 Phase 4 Dronabinol;Ethanol;Placebo Dronabinol;Placebo Ethanol
22 Assessment of NADA Acupuncture for Treatment of Withdrawal Symptoms During Gradual Opioid Withdrawal in Chronic Pain Patients Not yet recruiting NCT03397212 Phase 4
23 Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome Not yet recruiting NCT04298853 Phase 4 Morphine PRN;Morphine scheduled
24 Phenobarbital Versus Ativan for Refractory Alcohol Withdrawal Treatment in the Intensive Care Unit Not yet recruiting NCT04156464 Phase 4 Phenobarbital;Lorazepam
25 A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD) Terminated NCT01362205 Phase 4 Dexmedetomidine;Placebos
26 Evaluation of Pregabalin's Abuse Liability and Its Effects on Benzodiazepine Withdrawal Symptoms in Inpatients Undergoing Medically Assisted Benzodiazepine Withdrawal Terminated NCT02423018 Phase 4 Pregabalin;Placebo
27 Tight Hemodynamic Control in Patients Who Are Chronically on Metoprolol: A Study Comparing the Post Op Continuation of the Preoperative Oral Dose Beta Blockers to Intravenous Esmolol Titrated to a Target Heart Rate (HR) Terminated NCT01404767 Phase 4 Esmolol;Metoprolol
28 Treatment for Alcohol Dependence With Gabapentin: A Double Blind Placebo Controlled Randomized Clinical Trial Terminated NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
29 A Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Phenobarbital and Ketamine Adjunctive Therapies in the Treatment of Alcohol Withdrawal Syndrome Withdrawn NCT03788889 Phase 4 Ketamine;Phenobarbital;Lorazepam;Placebo A;Placebo B
30 Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal Completed NCT00980044 Phase 2, Phase 3 Tramadol;Placebo
31 Efficacy and Safety of Levetiracetam in the Inpatient Treatment of Alcohol Withdrawal Syndrome [Sicherheit Und Wirksamkeit Von Levetiracetam (Keppra) für Die Behandlung Des stationären Alkoholentzugsyndroms] Completed NCT00146471 Phase 3 Levetiracetam;Placebo
32 Comparison of a Fixed-Schedule Therapy Versus a Symptom-Triggered Therapy for Alcohol Withdrawal Syndrome in Medical Out-Patients Completed NCT00136617 Phase 3 chlordiazepoxide
33 A Phase 3, Open-Label, Safety Study of Lofexidine Completed NCT02363998 Phase 3 Lofexidine
34 Buprenorphine/Naloxone Versus Clonidine For Out-patient Opiate Detoxification Completed NCT00032968 Phase 3 Buprenorphine/naloxone
35 Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification Completed NCT00032955 Phase 3 Buprenorphine/naloxone
36 A Randomized, Double-Blind, Multiple-Dose, Parallel Group Study to Evaluate the Potential of Withdrawal Effects Following Administration of Oxycodone/Naltrexone Capsules and Oxycodone in Methadone-Maintained Opioid-Dependent Subjects Completed NCT02391571 Phase 3 Oxycodone/Naltrexone Capsules;Oxycodone;Placebo
37 Pharmacogenetics, Emotional Reactivity and Smoking Cessation: Genetic Differences in Limbic Activation Associated With Nicotine Withdrawal Completed NCT00664404 Phase 3
38 Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14) Completed NCT01863186 Phase 3 Lofexidine HCl;Placebo;Open Label Lofexidine HCL
39 Baclofen to Prevent Agitation in Alcohol Addicted Patients in ICU: Study Protocol for a Randomised Controlled Against Placebo Trial Completed NCT02723383 Phase 3 BACLOFEN;PLACEBO
40 Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers Completed NCT00018174 Phase 3 Fluoxetine;Placebo
41 The Effect of Aromatherapy on Neonatal Abstinence Syndrome and Salivary Cortisol Levels Completed NCT03097484 Phase 3 lavender and chamomile essential oils
42 Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms Completed NCT00202514 Phase 2, Phase 3 divalproex sodium extended release
43 The Efficacy of N-acetylcysteine Versus Placebo for the Treatment of Metamphetamine Withdrawal Symptoms Recruiting NCT04405193 Phase 2, Phase 3 N-acetyl cysteine;Placebo
44 Multicenter Randomized Placebo Controlled Trial Assessing the Efficacy of Oral Adjuvant Magnesium Supplementation in the Treatment of Alcohol Withdrawal Syndrome Recruiting NCT03033823 Phase 3 Magnesium;Placebo Oral Tablet
45 NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs): Infant Neurodevelopmental Outcomes (INO) Sub-study Not yet recruiting NCT03911739 Phase 3 Buprenorphine Injection;Buprenorphine Sublingual Product
46 NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs): a Pragmatic Randomized Trial Comparing Extended-release and Daily Buprenorphine Formulations: Conceptual Model Assessments (CMA) Sub-study Not yet recruiting NCT03911466 Phase 3 Buprenorphine Injection;Buprenorphine Sublingual Product
47 Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs): a Pragmatic Randomized Trial Comparing Extended-release and Daily Buprenorphine Formulations Not yet recruiting NCT03918850 Phase 3 Buprenorphine Injection;Buprenorphine Sublingual Product
48 Pragmatic, Randomized, Blinded Trial to Shorten Pharmacologic Treatment of Newborns With Neonatal Opioid Withdrawal Syndrome (NOWS) Not yet recruiting NCT04214834 Phase 3 Morphine;Methadone
49 Preventing Alcohol Withdrawal Syndrome With Oral Baclofen: A Randomized, Placebo Controlled Trial Terminated NCT02052440 Phase 3 Baclofen;Placebo
50 ASSESSMENT OF THE SAFETY AND BENEFIT OF PROSPECTIVE IMMUNOSUPPRESSIVE DRUG WITHDRAWAL IN LIVER TRANSPLANTATION AND PREDICTION OF OPERATIONAL TOLERANCE Unknown status NCT00647283 Phase 2

Search NIH Clinical Center for Withdrawal Disorder

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carbamazepine
Clonidine
CLONIDINE HCL PWDR
Clonidine Hydrochloride
Haloperidol
haloperidol decanoate
Haloperidol lactate
Hydroxyzine
Hydroxyzine Hydrochloride
Hydroxyzine Pamoate
Lorazepam
Perphenazine
Procaine
Procaine hydrochloride

Genetic Tests for Withdrawal Disorder

Anatomical Context for Withdrawal Disorder

MalaCards organs/tissues related to Withdrawal Disorder:

40
Brain, Prostate, Heart, Liver, Myeloid, Cortex, Testes

Publications for Withdrawal Disorder

Articles related to Withdrawal Disorder:

(show top 50) (show all 4045)
# Title Authors PMID Year
1
Clinical efficacy of alternative antiandrogen therapy in Japanese men with relapsed prostate cancer after first-line hormonal therapy. 61 54
17302569 2007
2
Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy. 54 61
16037707 2005
3
Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. 61 54
15166229 2004
4
3 beta-acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity. 54 61
12672951 2003
5
Behavioral effects of potentiated antibodies to morphine and mu-opioid receptors during withdrawal syndrome. 54 61
12949640 2003
6
Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone. 61 54
11803262 2002
7
Androgen receptor mutations in carcinoma of the prostate: significance for endocrine therapy. 54 61
12083956 2001
8
Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance. 61 54
11085345 2000
9
Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. 54 61
9636157 1998
10
Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression. 61 54
9634122 1998
11
[Molecular biological aspect]. 54 61
9617316 1998
12
Incidence and characteristics of antiandrogen withdrawal syndrome in prostate cancer after treatment with chlormadinone acetate. 54 61
9743699 1998
13
[An equivalent of anti-androgen withdrawal syndrome: decrease of prostate specific antigen and clinical response to estramustine phosphate withdrawal]. 54 61
9180872 1997
14
The antiandrogen withdrawal syndrome. 61 54
9144890 1997
15
Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. 54 61
8827083 1996
16
Hyperadrenergic state following acute withdrawal from clonidine used at supratherapeutic doses. 54 61
8726097 1996
17
Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. 54 61
7510915 1994
18
Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. 61 54
7679759 1993
19
alpha N-acetyl human beta-endorphin-(1-31) alleviates the morphine withdrawal syndrome in rodents: a comparative study with clonidine. 61 54
1608292 1992
20
Reversible neurologic abnormalities associated with prolonged intravenous midazolam and fentanyl administration. 54 61
1919899 1991
21
Lipid profile dysregulation predicts alcohol withdrawal symptom severity in individuals with alcohol use disorder. 61
32335269 2020
22
Alcohol-induced thrombocytopenia: Current review. 61
32330589 2020
23
Ceftriaxone Attenuated Anxiety-Like Behavior and Enhanced Brain Glutamate Transport in Zebrafish Subjected to Alcohol Withdrawal. 61
32185643 2020
24
Make Mission Impossible Feasible: The Experience of a Multidisciplinary Team Providing Treatment for Alcohol Use Disorder to Homeless Individuals. 61
32533164 2020
25
Tapering with Pharmaceutical GHB or Benzodiazepines for Detoxification in GHB-Dependent Patients: A Matched-Subject Observational Study of Treatment-as-Usual in Belgium and The Netherlands. 61
32319006 2020
26
Short-term nicotine deprivation alters dorsal anterior cingulate glutamate concentration and concomitant cingulate-cortical functional connectivity. 61
32559759 2020
27
A Core Outcome Set for Neonatal Opioid Withdrawal Syndrome. 61
32493710 2020
28
The Reemergence of Ketamine for Treatment in Critically Ill Adults. 61
32317593 2020
29
Complicated Alcohol Withdrawal-An Unintended Consequence of COVID-19 Lockdown. 61
32400859 2020
30
Protagonist Role of Opioidergic System on Post-Traumatic Stress Disorder and Associated Pain. 61
32492768 2020
31
Acute Opioid Withdrawal Mimicking Postoperative Joint Infection Following anterior cruciate ligament (ACL) Reconstruction: A Case Report. 61
32569260 2020
32
A machine learning approach to risk assessment for alcohol withdrawal syndrome. 61
32418843 2020
33
Evaluation of a Novel Protocol for Assessment and Treatment of Alcohol Withdrawal Syndrome in Psychiatric Inpatients. 61
32490573 2020
34
Pharmacotherapeutic management of acute alcohol withdrawal syndrome in critically Ill patients. 61
32281894 2020
35
Lead poisoning; a neglected potential diagnosis in abdominal pain. 61
32375657 2020
36
Iatrogenic withdrawal syndrome in specialty pediatric critical care. 61
32471722 2020
37
The Neuropsychiatric Iceberg Under Withdrawal Syndrome. 61
32355978 2020
38
Withdrawal Syndrome After Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia in the Russian Prospective Study RU-SKI. 61
32146103 2020
39
Front-loaded diazepam versus lorazepam for treatment of alcohol withdrawal agitated delirium. 61
32402500 2020
40
State Policies That Treat Prenatal Substance Use As Child Abuse Or Neglect Fail To Achieve Their Intended Goals. 61
32364867 2020
41
Inhibitory transmission in the bed nucleus of the stria terminalis in male and female mice following morphine withdrawal. 61
30963693 2020
42
Persistent cognitive and affective alterations at late withdrawal stages after long-term intermittent exposure to tobacco smoke or electronic cigarette vapour: Behavioural changes and their neurochemical correlates. 61
32450347 2020
43
Nectin-2α is localized at cholinergic neuron dendrites and regulates synapse formation in the medial habenula. 61
32452538 2020
44
GHB concentration in a related post-mortem case. 61
32323711 2020
45
Incidence and risk factors for readmission to a paediatric intensive care unit. 61
31576633 2020
46
Tinnitus associated with benzodiazepine withdrawal syndrome: A case report and literature review. 61
32420008 2020
47
Positive association between neighborhood retail alcohol outlet access and hospital admissions for alcohol withdrawal syndrome in New Orleans. 61
32401180 2020
48
Survey of analgesia and sedation in pediatric intensive care units in Japan. 61
31910495 2020
49
Fundamental sex differences in morphine withdrawal-induced neuronal plasticity. 61
32345917 2020
50
Impact of Traumatic Brain Injury on Clinical Institute Withdrawal Assessment Use in Trauma Patients: A Descriptive Study. 61
32304351 2020

Variations for Withdrawal Disorder

Expression for Withdrawal Disorder

Search GEO for disease gene expression data for Withdrawal Disorder.

Pathways for Withdrawal Disorder

Pathways related to Withdrawal Disorder according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.55 POMC PNOC PENK PDYN OPRM1 OPRL1
2
Show member pathways
12.75 TSPO POMC PNOC PENK PDYN OPRM1
3
Show member pathways
12.74 POMC FOS DRD2 DRD1 CRHR1 CRH
4 12.15 POMC FOS DRD2 DRD1
6 11.9 POMC DRD1 CRHR1 CRH
7
Show member pathways
11.78 PDYN FOS DRD2 DRD1
8 11.73 POMC OPRM1 OPRD1 FOS
9 11.66 NCOA4 KLK3 AR
10 11.53 POMC FOS CRHR1 CRH
11 11.41 NCOA4 KLK3 AR
12
Show member pathways
11.3 KLK3 FOS AR
13 10.79 FOS AR
14 10.18 POMC CRHR1 CRH

GO Terms for Withdrawal Disorder

Cellular components related to Withdrawal Disorder according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 10.03 OPRM1 OPRL1 OPRK1 OPRD1 DRD2 DRD1
2 synapse GO:0045202 9.95 PNOC OPRK1 DRD2 DRD1 CRH CNR1
3 neuronal cell body GO:0043025 9.85 PNOC PENK PDYN OPRK1 CRH
4 neuron projection GO:0043005 9.85 OPRM1 OPRL1 OPRK1 OPRD1 FOS CRHR1
5 perikaryon GO:0043204 9.72 PENK OPRM1 OPRK1 DRD2 CRH
6 dendrite GO:0030425 9.7 PNOC PENK PDYN OPRM1 OPRK1 DRD2
7 GABA-ergic synapse GO:0098982 9.67 DRD2 DRD1 CNR1
8 integral component of postsynaptic membrane GO:0099055 9.56 OPRM1 OPRK1 DRD2 DRD1
9 axon terminus GO:0043679 9.43 PNOC PENK PDYN OPRK1 OPRD1 DRD2
10 spine apparatus GO:0097444 9.4 OPRM1 OPRD1
11 integral component of presynaptic membrane GO:0099056 9.1 OPRM1 OPRK1 OPRD1 DRD2 DRD1 CNR1

Biological processes related to Withdrawal Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.22 POMC PNOC PENK OPRM1 OPRL1 OPRK1
2 response to drug GO:0042493 10.04 TSPO FOS DRD2 DRD1 CRH
3 cytokine-mediated signaling pathway GO:0019221 10.02 POMC OPRM1 OPRD1 FOS
4 chemical synaptic transmission GO:0007268 10.02 PNOC PENK PDYN OPRK1 CRH
5 cell-cell signaling GO:0007267 9.99 POMC DRD2 DRD1 AR
6 aging GO:0007568 9.98 TSPO PENK FOS CNR1
7 response to lipopolysaccharide GO:0032496 9.97 PENK OPRM1 FOS CNR1
8 G protein-coupled receptor signaling pathway GO:0007186 9.97 POMC PNOC PENK PDYN OPRM1 OPRL1
9 response to ethanol GO:0045471 9.91 PENK OPRM1 OPRK1 DRD2 CRH CNR1
10 response to toxic substance GO:0009636 9.89 PENK FOS DRD2
11 female pregnancy GO:0007565 9.89 PNOC FOS CRHR1 CRH
12 locomotory behavior GO:0007626 9.89 PENK OPRM1 OPRK1 DRD2 DRD1
13 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.86 OPRM1 OPRK1 OPRD1
14 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.86 DRD2 DRD1 CRHR1 CNR1
15 sensory perception of pain GO:0019233 9.85 PENK OPRM1 OPRL1 OPRK1 CNR1
16 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.84 OPRM1 OPRD1 DRD1 CNR1
17 response to nicotine GO:0035094 9.83 PENK DRD2 CNR1
18 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.83 OPRM1 OPRL1 OPRK1 OPRD1
19 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.82 OPRL1 DRD2 DRD1
20 response to radiation GO:0009314 9.81 PENK OPRM1 OPRK1
21 regulation of sensory perception of pain GO:0051930 9.81 OPRM1 OPRL1 OPRK1 OPRD1
22 associative learning GO:0008306 9.8 DRD2 DRD1 CRH
23 negative regulation of blood pressure GO:0045776 9.8 OPRL1 DRD2 CNR1
24 eating behavior GO:0042755 9.78 OPRM1 OPRL1 OPRK1 OPRD1
25 behavioral response to cocaine GO:0048148 9.76 OPRK1 DRD2 DRD1
26 synaptic transmission, dopaminergic GO:0001963 9.75 DRD2 DRD1 CRH
27 estrous cycle GO:0044849 9.74 OPRM1 OPRL1 OPRK1
28 response to corticosterone GO:0051412 9.73 FOS CRH
29 startle response GO:0001964 9.73 PENK DRD2
30 response to cocaine GO:0042220 9.73 OPRM1 OPRK1 DRD2 DRD1 CRH CNR1
31 prepulse inhibition GO:0060134 9.72 DRD2 DRD1
32 behavioral response to ethanol GO:0048149 9.72 OPRM1 DRD2
33 dopamine metabolic process GO:0042417 9.72 DRD2 DRD1
34 regulation of synaptic transmission, GABAergic GO:0032228 9.72 DRD2 CNR1
35 negative regulation of voltage-gated calcium channel activity GO:1901386 9.72 OPRL1 DRD2 CRHR1
36 response to morphine GO:0043278 9.72 PENK OPRM1 OPRK1 DRD2 CNR1
37 behavior GO:0007610 9.71 OPRL1 OPRK1
38 regulation of systemic arterial blood pressure GO:0003073 9.71 KLK3 AR
39 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.71 DRD2 DRD1
40 positive regulation of urine volume GO:0035810 9.71 OPRL1 DRD2
41 grooming behavior GO:0007625 9.7 DRD2 DRD1
42 maternal behavior GO:0042711 9.7 OPRK1 DRD1
43 locomotory exploration behavior GO:0035641 9.7 PENK CRH
44 striatum development GO:0021756 9.7 DRD2 DRD1
45 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.69 OPRM1 DRD1
46 peristalsis GO:0030432 9.69 DRD2 DRD1
47 parturition GO:0007567 9.68 CRHR1 CRH
48 positive regulation of behavioral fear response GO:2000987 9.68 PENK CRH
49 negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0106072 9.67 OPRM1 OPRL1
50 cerebral cortex GABAergic interneuron migration GO:0021853 9.67 DRD2 DRD1

Molecular functions related to Withdrawal Disorder according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.92 OPRM1 OPRL1 OPRK1 OPRD1 DRD2 DRD1
2 peptide binding GO:0042277 9.67 OPRM1 OPRL1 OPRK1 OPRD1
3 neuropeptide hormone activity GO:0005184 9.58 PNOC PENK CRH
4 dopamine binding GO:0035240 9.49 DRD2 DRD1
5 receptor serine/threonine kinase binding GO:0033612 9.48 OPRK1 OPRD1
6 dopamine neurotransmitter receptor activity GO:0004952 9.46 DRD2 DRD1
7 androgen binding GO:0005497 9.43 TSPO AR
8 opioid receptor binding GO:0031628 9.43 PNOC PENK PDYN
9 opioid peptide activity GO:0001515 9.33 PNOC PENK PDYN
10 neuropeptide binding GO:0042923 9.26 OPRM1 OPRL1 OPRK1 OPRD1
11 opioid receptor activity GO:0004985 8.92 OPRM1 OPRL1 OPRK1 OPRD1

Sources for Withdrawal Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....